These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 19358672)

  • 1. Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis.
    Lamaris GA; Ben-Ami R; Lewis RE; Chamilos G; Samonis G; Kontoyiannis DP
    J Infect Dis; 2009 May; 199(9):1399-406. PubMed ID: 19358672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Voriconazole pre-exposure selects for breakthrough mucormycosis in a mixed model of Aspergillus fumigatus-Rhizopus oryzae pulmonary infection.
    Lewis RE; Liao G; Wang W; Prince RA; Kontoyiannis DP
    Virulence; 2011; 2(4):348-55. PubMed ID: 21788730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies.
    Espinel-Ingroff A; Johnson E; Hockey H; Troke P
    J Antimicrob Chemother; 2008 Mar; 61(3):616-20. PubMed ID: 18222957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole.
    Chamilos G; Lewis RE; Kontoyiannis DP
    Antimicrob Agents Chemother; 2006 Jan; 50(1):96-103. PubMed ID: 16377673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does pre-exposure of Aspergillus fumigatus to voriconazole or posaconazole in vitro affect its virulence and the in vivo activity of subsequent posaconazole or voriconazole, respectively? A study in a fly model of aspergillosis.
    Lamaris GA; Ben-Ami R; Lewis RE; Kontoyiannis DP
    J Antimicrob Chemother; 2008 Sep; 62(3):539-42. PubMed ID: 18544603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study of fungicidal activities of voriconazole and amphotericin B against hyphae of Aspergillus fumigatus.
    Krishnan S; Manavathu EK; Chandrasekar PH
    J Antimicrob Chemother; 2005 Jun; 55(6):914-20. PubMed ID: 15824093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis.
    Chamilos G; Lewis RE; Hu J; Xiao L; Zal T; Gilliet M; Halder G; Kontoyiannis DP
    Proc Natl Acad Sci U S A; 2008 Jul; 105(27):9367-72. PubMed ID: 18583479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between the E test and the CLSI M-38 A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus.
    Guinea J; Peláez T; Alcalá L; Bouza E
    Diagn Microbiol Infect Dis; 2007 Mar; 57(3):273-6. PubMed ID: 17141455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Sensititre YeastOne with the NCCLS M38-A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus.
    Guinea J; Peláez T; Alcalá L; Bouza E
    Diagn Microbiol Infect Dis; 2006 Sep; 56(1):53-5. PubMed ID: 16650953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-antifungal effect of amphotericin B and voriconazole against Aspergillus fumigatus analysed by an automated method based on fungal CO2 production: dependence on exposure time and drug concentration.
    Chryssanthou E; Sjölin J
    J Antimicrob Chemother; 2004 Nov; 54(5):940-3. PubMed ID: 15471994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
    Kaya AD; Kiraz N
    Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-antifungal effect of amphotericin B and voriconazole against germinated Aspergillus fumigatus conidia.
    Chryssanthou E; Loebig A; Sjölin J
    J Antimicrob Chemother; 2008 Jun; 61(6):1309-11. PubMed ID: 18367461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibility.
    Spreghini E; Orlando F; Giannini D; Barchiesi F
    J Antimicrob Chemother; 2010 Oct; 65(10):2158-63. PubMed ID: 20667887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli.
    Lionakis MS; Lewis RE; Torres HA; Albert ND; Raad II; Kontoyiannis DP
    Diagn Microbiol Infect Dis; 2005 May; 52(1):15-20. PubMed ID: 15878437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
    Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
    Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Preexposure to Triazoles on Susceptibility and Virulence of Rhizopus oryzae.
    Bellanger AP; Albert ND; Lewis RE; Walsh TJ; Kontoyiannis DP
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7830-2. PubMed ID: 26392499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole.
    Imhof A; Balajee SA; Fredricks DN; Englund JA; Marr KA
    Clin Infect Dis; 2004 Sep; 39(5):743-6. PubMed ID: 15356792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of posaconazole in treatment of experimental disseminated zygomycosis.
    Dannaoui E; Meis JF; Loebenberg D; Verweij PE
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3647-50. PubMed ID: 14576138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of amphotericin B lipid formulations and triazoles with human polymorphonuclear leucocytes for antifungal activity against Zygomycetes.
    Simitsopoulou M; Roilides E; Maloukou A; Gil-Lamaignere C; Walsh TJ
    Mycoses; 2008 Mar; 51(2):147-54. PubMed ID: 18254752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy.
    Trifilio SM; Bennett CL; Yarnold PR; McKoy JM; Parada J; Mehta J; Chamilos G; Palella F; Kennedy L; Mullane K; Tallman MS; Evens A; Scheetz MH; Blum W; Kontoyiannis DP
    Bone Marrow Transplant; 2007 Apr; 39(7):425-9. PubMed ID: 17310132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.